Aurobindo Pharma gets first US nod for alfuzosin HCL
MUMBAI, Nov 19 (Reuters) - The U.S. Food and Drug Administration has tentatively approved Aurobindo Pharma Ltd's (ARBN.BO: Quote, Profile, Research) alfuzosin hydrochloride extended release tablets, the regulator's website showed.
The drug is used to treat a non-cancerous enlarged prostate condition. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved
Pledge to support economies
G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured. Full Article | Related Story
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article





India
US
UK










